China Biotech Services Holdings Full Year 2024 Earnings: HK$0.20 loss per share (vs HK$0.099 loss in FY 2023)

China Biotech Services Holdings (HKG:8037) Full Year 2024 Results

Key Financial Results

• Revenue: HK$70.5m (down 67% from FY 2023).
• Net loss: HK$198.1m (loss widened by 108% from FY 2023).
• HK$0.20 loss per share (further deteriorated from HK$0.099 loss in FY 2023).

The end of cancer? These 15 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

All figures shown in the chart above are for the trailing 12 month (TTM) period

China Biotech Services Holdings shares are down 5.8% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 3 warning signs for China Biotech Services Holdings (of which 2 make us uncomfortable!) you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.